VRTX (Vertex Pharmaceuticals): A Beat, A Raise — And 75% Of Revenue Just Shrank. Q2 2026

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 — Reported after the close on August 3 (three months ended June 30, 2026). Total revenue $3,333.9M, +12.5%, ahead of the ~$3.23B expected. GAAP EPS $4.31 vs $3.99; non-GAAP EPS $4.73 vs the $4.74 expected — a one-cent miss. FY2026 revenue guidance RAISED to $13.1-13.2B from $12.95-13.1B, with every expense line left unchanged. CASGEVY $76.4M, +151%. JOURNAVX $49.6M on ~535,000 prescriptions. Cash and marketable securities $13.64B with zero debt. The stock closed at $470.72, 11% below the $529.59 high it made on July 6 — the day it agreed to buy Crinetics. The number nobody read: TRIKAFTA/KAFTRIO — 74.9% of Vertex's entire revenue — did $2,497.2M against $2,551.1M, a 2.1% DECLINE, and it fell 4.6% across the first half. The money did not leave, it rotated into ALYFTREK ($573.6M vs $156.8M), which is deliberate and smart. But cystic fibrosis is 96.2% of revenue in a patient pool already ~95% penetrated, the four diversification pillars are 3.8% of revenue, and R&D spending was FLAT while SG&A rose 37.1%. THE CALL: HOLD (3/5, A REAL MONOPOLY, FULLY PRICED — AND A $10B BET NOBODY ELSE WOULD MAKE) — base-case value ~$415.0 vs ~$470.72 today. KEY METRICS: - THE CALL: HOLD 3/5 - fair value ~$415 vs the $470.72 close (-12%); Street average $549.21 (47 buy / 8 hold / 1 sell, 56 analysts, range $350-$616, +17%), so we DIFFER on the rating and are more CAUTIOUS on the number. DCF GRID (bear/base/bull x 7.5/8.5/9.5%): $331-289-257, $470-396-343, $653-534-452. Probability-weighted 25/50/25 gives $404 at 8.5% and $481 at 7.5%; we sit at $415, respecting the low-beta argument without paying for it. Base case uses TTM free cash flow of $3.71B (operating cash flow less capex, from the filings) growing 8% then 5%, 2.5% terminal. REVERSE DCF: at $470.72 the operating business is priced at $108.4B, which at 8.5% with 2.5% terminal growth demands ~$6.50B of perpetual FCF starting now - 75% more cash than today, and it has to come from the 3.8% of revenue that is not cystic fibrosis. - THE UNDER-COVERED ANGLE - THE BIGGEST MEDICINE IS SHRINKING, AND THE SECOND ACT IS 3.8% OF REVENUE. TRIKAFTA/KAFTRIO did $2,497.2M, DOWN 2.1% year over year and down 4.6% across the first half, while still being 74.9% of all revenue. That is a deliberate conversion - ALYFTREK went from $156.8M to $573.6M (+266%), is once-daily, carries a lower royalty burden and extends patent protection from 2037 to 2039 - so the franchise is fine. The issue is shape: cystic fibrosis is 96.2% of revenue ($3,207.9M) in a population Vertex already treats ~95% of. Revenue grew 7.8% in Q1, 12.5% in Q2, and the raised guidance implies ~9.0% in H2. Non-CF revenue is $126.0M, or 3.78% of the company; H1 non-CF was $197.9M against a '$0.5B or greater' full-year guide, so H2 needs $302M. - ALSO: R&D WENT FLAT, SG&A ROSE 37%, AND $10B IS LEAVING FOR A SOLE-BIDDER DEAL. Research and development rose just 1.6% to $993.8M - and across the first half it was $1,955.4M vs $1,958.1M, DOWN 0.1%. SG&A rose 37.1% to $582.2M. So 12.5% revenue growth produced 3.2% non-GAAP net income growth; non-GAAP operating margin fell 202bps from 44.7% to 42.7% and gross margin slipped from 86.3% to 85.3%. Computed from the release: ~535,000 JOURNAVX prescriptions and $49.6M of revenue is $92.71 per filled prescription, against a ~$232.50 list price for a 7-day course - about 40 cents on the list-price dollar (Q1 was $79.45, so it is improving fast). Meanwhile Vertex is paying $85.00/share cash for Crinetics, ~$10.0B equity value (~$8.8B net of cash), a 102% premium to the $42.03 undisturbed price, funded partly by a $4.5B bridge. The proxy shows Vertex was the SOLE bidder: the only other party that engaged concluded it could not go above $6B and withdrew. Crinetics did $7.7M of revenue and lost $465.3M in 2025, and Vertex says the deal is not accretive to non-GAAP operating income until 2029. What to watch: Bullish: povetacicept approved on the November 30 PDUFA date with a broad IgAN label; non-CF revenue clearing the $500M full-year guide (needs $302M in H2 vs $197.9M in H1); JOURNAVX net revenue per prescription above $120. All three and we move toward $520. Bearish: non-CF missing the $500M guide; TRIKAFTA falling again WHILE ALYFTREK decelerates; the combined expense guide breaking upward as Crinetics integrates on top of the JOURNAVX launch. Any two and we are nearer $350. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.